CECLOR
LOE ApproachingNDAORALFOR SUSPENSION
Approved
Apr 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR is an oral suspension small-molecule antibiotic approved in 1979 by Eli Lilly. The drug treats bacterial infections across multiple indications via oral administration. Its exact mechanism and indication profile are not publicly detailed in this dataset.
LOE Approaching
Mature product approaching loss of exclusivity with modest competitive pressure (30%), indicating a contracting commercial team focused on managed decline and potential cost optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CECLOR carries minimal active recruiting signal (0 linked jobs), reflecting its mature, LOE-approaching status. Career opportunities are primarily in managed decline roles: brand stewardship, generic transition strategy, and cost containment rather than growth-stage positions.
Brand ManagerProduct Manager
Worked on CECLOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.